News

BioHarvest outlines path to $11M–$12M quarterly revenue for adjusted EBITDA breakeven while expanding VINIA portfolio and CDMO pipeline
Discover how BioHarvest Sciences achieved 47% revenue growth in Q1 2025, advanced CDMO milestones, and expanded into new product categories.
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
BioHarvest Sciences Inc. ( NASDAQ: BHST) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Matt Hewitt - Craig-Hallum Capital Group Amit Dayal - H.C. Wainwright Susan Anderson - Canaccord ...